Pfizer Declares First-Quarter 2025 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
December 16, 2024 4:14 AM ESTGoldman Sachs analyst Chris Shibutani reiterated a Buy rating and $33.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Ahead of PFE's 2025 Guidance call (Tuesday, December 17) we outline our expectations for the guide and commentary on the upcoming year. Overall, we anticipate that PFE management will guide to earnings (EPS) in the mid-to-high $2 range with core business growth offset by... More



